Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk

DNA and Cell Biology

Volumn 31, Issue 6, 2012, Pages 975-982

  Wang, Mingsong ^a   Lang, Xilong ^b   Cui, Shitao ^a   Zou, Liangjian ^b   Cao, Jia ^a   Wang, Sheng ^a   Wu, Xintian ^a  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; EFFECT SIZE; EMBASE; ENZYME ACTIVITY; ETHNICITY; GENOTYPE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAMPLE SIZE; SYSTEMATIC REVIEW;

ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CORONARY DISEASE; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 84864067411     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1478     Document Type: Article

References (70)

1. Aydin, M., Gokkusu, C., Ozkok, E., Tulubas, F., Unlucerci, Y., Pamukcu, B., Ozbek, Z., and Umman, B. (2009). Association of genetic variants in Methylenetetrahydrofolate Reductase and Paraoxonase-1 genes with homocysteine, folate and vitamin B12 in coronary artery disease. Mol Cell Biochem 325, 199-208.
2. Ayub, A., Mackness, M.I., Arrol, S., Mackness, B., Patel, J., and Durrington, P.N. (1999). Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 19, 330-335.
3. Azarsiz, E., Kayikcioglu, M., Payzin, S., and Yildirim Sözmen, E. (2003). PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol 91, 43-51.
4. Bai, L., Ma, A.Q., and Di, T. (2002). Correlation of serum paraoxonase activity with coronary heart disease. Di Si Jun Yi Da Xue Xue Bao 23, 3.
5. Bhattacharyya, T., Nicholls, S.J., Topol, E.J., et al. (2008). Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299, 1265-1276.
6. Birjmohun, R.S., Vergeer, M., Stroes, E.S., et al. (2009). Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. PLoS One 4, e6809.
7. Blatter Garin, M.C., Moren, X., James, R.W. (2006). Paraoxonase- 1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res 47, 515-520.
8. Chi, D.S., Ling, W.H., Ma, J., Xia, M., Hou, M.J., Wang, Q., Zhu, H.L., Tang, Z.H., and Yu, X.P. (2006). Study of the association between paraoxonase1 55 Met/Leu, paraoxonase2 148 Ala/ Gly and manganese superoxide dismutase (MnSOD) 9 Ala/ Val genetic polymorphisms and coronary heart disease. Zhonghua Liu Xing Bing Xue Za Zhi 27, 808-813.
9. DerSimonian, R., and Laird, N. (1986). Meta-analysis in clinical trials. Control Clin Trials 7, 177-188.
10. Durrington, P.N., Mackness, B., and Mackness, M.I. (2001). Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21, 473-480.
11. Egger, M., Davey Smith, G., Schneider, M., and Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-634.
12. Ferré, N., Tous, M., Paul, A., Zamora, A., Vendrell, J.J., Bardaj́, A., Camps, J., Richart, C., and Joven, J. (2002). Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 35, 197-203.
13. Friedrich, J.O., Adhikari, N.K., and Beyene, J. (2008). The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol 8, 32.
14. Gamboa, R., Regalado, J.C., Huesca-Gómez, C., Posadas-Romero, C., Verdejo Paris, J., Vargas-Alarcón, G., and Pérez- Méndez, O. (2008). Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease. Arch Cardiol Mex 78, 360-368.
15. Göçmen, A.Y., Gümüsxlü, S., and Semiz, E. (2004). Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. Clin Cardiol 27, 426-430.
16. Göçmen, A.Y., Sahin, E., Semiz, E., and Gümusxlü, S. (2008). Is elevated serum ceruloplasmin level associated with increased risk of coronary artery disease? Can J Cardiol 24, 209-212.
17. Hasselwander, O., Savage, D.A., McMaster, D., Loughrey, C.M., McNamee, P.T., Middleton, D., Nicholls, D.P., Maxwell, A.P., and Young, I.S. (1999). Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 56, 289-298.
18. Itahara, T., Suehiro, T., Ikeda, Y., et al. (2000). Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb 7, 152-8.
19. James, R.W., Leviev, I., Ruiz, J., Passa, P., Froguel, P., and Garin, M.C. (2000). Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49, 1390-1393.
20. Kaman, D., Ilhan, N., Metin, K., Akbulut, M., and Ustündag, B. (2009). A preliminary study of human paraoxonase and PON 1 L/M55-PON 1 Q/R 192 polymorphisms in Turkish patients with coronary artery disease. Cell Biochem Funct 27, 88-92.
21. Karakaya, A., Ibisx, S., Kural, T., Köse, S.K., and Karakaya, A.E. (1999). Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chem Biol Interact 118, 193-200.
22. Kerkeni, M., Addad, F., Chauffert, M., Chuniaud, L., Miled, A., Trivin, F., and Maaroufi, K. (2006). Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 39, 821-825.
23. Kotur-Stevuljevic, J., Spasic, S., Stefanovic, A., et al. (2006). Paraoxonase-1 (PON1) activity, but not PON1(Q192R) phenotype, is a predictor of coronary artery disease in a middleaged Serbian population. Clin Chem Lab Med 44, 1206-1213.
24. Lacinski, M., Skorupski, W., Cieslinski, A., Sokolowska, J., Trzeciak, W.H., and Jakubowski, H. (2004). Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol (Noisy-le-grand) 50, 885-893.
25. Lakshmy, R., Ahmad, D., Abraham, R.A., Sharma, M., Vemparala, K., Das, S., Reddy, K.S., and Prabhakaran, D. (2010). Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J Med Res 131, 522-529.
26. Li, H.L., Liu, D.P., and Liang, C.C. (2003). Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 81, 766-779.
27. Li, S.Y., Li, J.Y., Wei, G., Ji, Q.D., and Wang, P.X. (2004). Study on the relationship between Paraoxonase-1 (PON-1) and Type 2 diabetes mellitus complicated by coronary artery disease. Tianjin Yi Yao 32, 273-276.
28. Liu, K.T., Zeng, G.F., Liu, G.X., Wang, Y., and Ding, C.F. (2000). The relation of serum paraoxonase activity and Gln-Arg 192 polymorphism with coronary heart disease. Lin Chuang Xin Xue Guan Bing Za Zhi 16, 148-150.
29. Lu, C., Gao, Y., Zhou, H., and Tian, H. (2008). The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose. Coron Artery Dis 19, 565-573.
30. Luo, Y.P., Ou, B.Q., Zhang, Y., Lian, Y., Guo, Y., and Zhao, S.P. (2008). Analysis of plasma paraoxonase 1 activity in patients with unstable angina. Zhongguo Yi Shi Za Zhi 10, 1121-1123.
31. Luo, Y.P., Zhao, S.P., Li, J., and Nie, S. (2002). The change of serum paranoxonase-1 activity in patients with acute coronary syndrom. Zhongguo Dong Mai Ying Hua Za Zhi 10, 341-344.
32. Lusis, A.J. (2000). Atherosclerosis. Nature 407, 233-241.
33. Mackness, B., Davies, G.K., Turkie, W., et al. (2001). Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21, 1451-1457.
34. Mackness, B., Durrington, P., McElduff, P., Yarnell, J., Azam, N., Watt, M., and Mackness, M. (2003). Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107, 2775-2779.
35. Mackness, B., Hine, D., McElduff, P., and Mackness, M. (2006). High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 186, 396-401.
36. Mackness, M.I, Abbott, C.A, Arrol, S., and Durrington, P.N. (1993a). The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 294, 829-835.
37. Mackness, M.I., Arrol, S., Abbott, C.A., and Durrington, P.N. (1993b). Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104, 129-135.
38. Mackness, M.I., Arrol, S., and Durrington, P.N. (1991). Paranoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett 286, 152-154.
39. Mackness, M.I., and Durrington, P.N. (1995). High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115, 243-253.
40. Martinelli, N., Girelli, D., Olivieri, O., et al. (2009). Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin Chem Lab Med 47, 432-440.
41. Mohamed, R.H., Mohamed, R.H., Karam, R.A., and Abd El- Aziz, T.A. (2010). The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clin Biochem 43, 553-558.
42. Najafi, M., Gohari, L.H., and Firoozrai, M. (2009). Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb Res 123, 503-510.
43. Parthasarathy, S., Barnett, J., and Fong, L.G. (1990). High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044, 275-283.
44. Qi, G.Q., Jia, B., Du, W.T., Yang, B.Z., Xia, Y., Li, Y.X., Li, B., and Wei, L.Y. (2006). Effects of the PON-1 activity to level of ox- LDL in patients with coronary artery disease. Lin Chuang Hui Cui 21, 1783-1784.
45. Qian, S.H., Qian, Q.W., Wang, S., and Wang, S.J. (2003). Relationship between arylesterase/paraoxonase1 Q192R gene polymorphism and diabetes mellitus complicated with coronary artery disease in population of Han nationnality of zhengzhou. Zhengzhou Da Xue Xue Bao Yi Xue Ban 38, 225-227.
46. Rahmani, M., Raiszadeh, F., Allahverdian, S., Kiaii, S., Navab, M., and Azizi, F. (2002). Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 162, 381-389.
47. Rodŕguez-Esparragón, F., Rodŕguez-Pérez, J.C., Hernández- Trujillo, Y., Maćas-Reyes, A., Medina, A., Caballero, A., and Ferrario, C.M. (2005). Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. Arterioscler Thromb Vasc Biol 25, 854-860.
48. Rosenzweig, A. (2007). Scanning the genome for coronary risk. N Engl J Med 357, 497-499.
49. Ross, R. (1993). The pathogenesis of atherosclerosis: a perspective for the1990s. Nature 362, 801-809.
50. Rozenberg, O., Rosenblat, M., Coleman, R., Shih, D.M., and Aviram, M. (2003). Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 34, 774-784.
51. Samani, N.J., Erdmann, J., Hall, A.S., et al. (2007). Genome-wide association analysis of coronary artery disease. N Engl J Med 357, 443-453.
52. Sarkar, P.D., T M, S., and Madhusudhan, B. (2006). Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. Clin Chim Acta 373, 77-81.
53. Sent́, M., Tomás, M., Marrugat, J., Elosua, R.; REGICOR Investigators. (2001). Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler Thromb Vasc Biol 21, 415-420.
54. Sentürk, T., Sarandöl, E., Güllülü, S., Erdinç, S., Ozdemir, B., Baran, I., and Aydinlar, A. (2008). Association between paraoxonase 1 activity and severity of coronary artery disease in patients with acute coronary syndromes. Acta Cardiol 63, 361-367.
55. Sharma, R., Singh, B., and Mahajan, M. (2007). PON1 activity is inversely related to LDL apoB carbonyl content in patients with coronary artery disease. Kaohsiung J Med Sci 23, 225-231.
56. Shih, D.M., Gu, L., Xia, Y.R., et al. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284-287.
57. Shih, D.M., Xia, Y.R., Wang, X.P., et al. (2000). Combined serum paraoxonase knockout/apolipoprotein E knock-out mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275, 17527-17535.
58. Singh, S., Venketesh, S., Verma, J.S., Verma, M., Lellamma, C.O., and Goel, R.C. (2007). Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus. Indian J Med Res 125, 783-787.
59. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L. (1989). Beyond cholesterol modifications of lowdensity lipoprotein that increase its atherogenicity. N Engl J Med 320, 915-924.
60. Stroup, D.F., Berlin, J.A., Morton, S.C., et al. (2000). Metaanalysis of observational studies in epidemiology, a proposal for reporting. JAMA 283, 2008-2012.
61. Suehiro, T., Ikeda, Y., Shiinoki, T., Inoue, M., Kumon, Y., Itahara, T., and Hashimoto, K. (2002). Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 9, 133-138.
62. Su, M.X., Cui, C.C., Cui, H.B., and Wang, X.Y. (2006). Analysis of paraoxonase activity in the patients with coronary artery disease. Zhongguo Dong Mai Ying Hua Za Zhi 14, 521-523.
63. Su, S.Y., Chen, J.H., Huang, J.F., Wang, X.L., Zhao, J.G., Shen, Y., Qiang, B.Q., and Gu, D.F. (2005). Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women. Chin Med J (Engl) 118, 1167-1174.
64. Troughton, J.A., Woodside, J.V., Yarnell, J.W., et al. (2008). Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis 197, 556-563.
65. Tward, A., Xia, Y.R., Wang, X.P., et al. (2002). Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106, 484-490.
66. van Himbergen, T.M., van der Schouw, Y.T., Voorbij, H.A., van Tits, L.J., Stalenhoef, A.F., Peeters, P.H., and Roest, M. (2008). Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis 199, 408-414.
67. Wang, M., Lang, X., Zou, L., Huang, S., and Xu, Z. (2011). Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies. Atherosclerosis 214, 377-385.
68. Wang, X., Fan, Z., Huang, J., et al. (2003). Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 23, 328-334.
69. Watson, A.D., Berliner, J.A., Hama, S.Y., La Du, B.N., Faull, K.F., Fogelman, A.M., and Navab, M. (1995). Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 96, 2882-2891.
70. Yang, Y.H., Xia, Y., Cui, D.S., Yuan, S.H., Geng, Y.L., Qi, G.Q., Liu, G., and Liu, K.S. (2007). Activity of paraoxonase-1 with coronary artery disease and severity of coronary artery lesions. Lin Chuang Hui Cui 22, 1761-1764.